Compare Dyne Therapeutics Inc. Common Stock (DYN) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs NIO Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while NIO Inc. trades at $3.4 (market cap $8.54B). The key difference: NIO Inc. is far larger — about 3× Dyne Therapeutics Inc. Common Stock's market cap, and NIO Inc. is more actively traded (34,684,903 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and NIO Inc. for 81 Days on average.
| DYN | NIO | |
|---|---|---|
Market Cap | $2.86B | $8.54B |
Volume | 3,341,579 | 34,684,903 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $7.42 |
52-Week Low | $14.60 | $3.37 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $2.18B | $6.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NIO trades at $3.41, down 1.73% on the day and near its 52-week low, reflecting a bearish technical trend. The company reported a net loss of $15.57 billion in 2025, though revenue grew to $87.49 billion and the net loss margin improved to -17.8%. Recent news highlights a strategic battery-swapping partnership with Geely, which could expand NIO's network but has weighed on the stock as investors assess profitability ahead of Q3 2026 earnings.
The outlook remains challenging due to persistent losses and intense EV competition, but analyst consensus is a Buy with a $6.23 price target, suggesting significant upside. Key risks include high debt, cash burn, and price wars in China's EV market, while opportunities lie in scaling the battery-swap network and potential margin improvement if delivery growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
